Biohaven secures $600m financing as it awaits FDA prodrug decision
Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ataxia drug.
Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ataxia drug.
What's Your Reaction?
